Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 2/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.43 |
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.39 |
| ▸ | SELE | P16581 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7594892 | 0.86 | LTB4R (0.62) | LTB4RHCAR2SELLSELPSELE | |
| SCHEMBL7594764 | 0.86 | LTB4R (0.47) | LTB4RHCAR2SELLSELPSELE | |
| SCHEMBL7593523 | 0.85 | LTB4R (0.45) | LTB4RHCAR2SELLSELPSELE | |
| SCHEMBL7593031 | 0.84 | SELL (0.44) | LTB4RSELLSELPSELEPOLB | |
| SCHEMBL7598800 | 0.83 | LTB4R (0.54) | LTB4RSELLSELPSELEPOLB | |
| SCHEMBL7591464 | 0.83 | LTB4R (0.51) | LTB4RHCAR2SELLSELPSELE | |
| SCHEMBL7596740 | 0.82 | LMNA (0.42) | LTB4RSELLSELPSELEF10 | |
| SCHEMBL7596121 | 0.81 | LTB4R (0.53) | LTB4RRAB9AMAPTALDH1A1LMNA | |
| SCHEMBL7594869 | 0.80 | LTB4R (0.41) | LTB4RSELLSELPSELEPOLB | |
| SCHEMBL7595154 | 0.80 | GAA (0.42) | LTB4RSELLSELPSELEPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | LTB4R 1803/4885HCAR2 4010/4885SELL 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.